<p>CareDx（纳斯达克：CDNA - 获取免费报告）在周六发布的研究报告中被华尔街 Zen 的投资分析师从 “买入” 评级下调至 “持有” 评级。</p>
<p>其他一些股票研究分析师最近也对 CDNA 发表了看法。BTIG Research 在 11 月 6 日的研究报告中将 CareDx 的目标价格从 22.00 美元上调至 25.00 美元，并给予该公司 “买入” 评级。Weiss Ratings 在 12 月 29 日的研究报告中重新发布了对 CareDx 的 “持有（c-）” 评级。Craig Hallum 在 1 月 6 日的研究报告中将 CareDx 的评级从 “买入” 下调至 “持有”，并设定了 26.00 美元的目标价格。Zacks Research 在 11 月 18 日的研究报告中将 CareDx 的评级从 “强烈卖出” 上调至 “持有”。最后，富国银行在 12 月 15 日的研究报告中将 CareDx 的目标价格从 14.00 美元上调至 18.00 美元，并给予该股票 “等权重” 评级。三位投资分析师对该股票给予了 “买入” 评级，六位分析师对该公司给予了 “持有” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “持有”，平均目标价格为 26.67 美元。</p>
<p><strong>查看我们对 CDNA 的最新分析</strong></p>
<h2>CareDx 股票上涨 6.1%</h2>
<p>纳斯达克：CDNA 周五开盘价为 19.47 美元。该公司的市值为 10 亿美元，市盈率为 16.36，贝塔值为 2.51。CareDx 的 12 个月低点为 10.96 美元，12 个月高点为 25.55 美元。该股票的 50 日简单移动平均线为 19.56 美元，200 日简单移动平均线为 16.11 美元。</p>
<p>CareDx（纳斯达克：CDNA - 获取免费报告）最后一次公布季度财报是在 11 月 4 日。该公司报告每股收益为 0.28 美元，超出分析师的共识预期 0.13 美元，超出幅度为 0.15 美元。CareDx 的净利润率为 19.65%，股本回报率为 20.15%。该季度的营业收入为 1 亿 006 万美元，而共识预期为 9,525 万美元。去年同期，该公司每股收益为（0.14）美元。CareDx 本季度的收入同比增长 20.7%。整体来看，股票研究分析师预计 CareDx 在本年度的每股收益为-0.9 美元。</p>
<h2>CareDx 的内部买卖</h2>
<p>在相关消息中，首席执行官 John Walter Hanna, Jr.于 1 月 22 日星期四出售了 19,280 股 CareDx 股票。该股票以平均价格 21.16 美元出售，总价值为 407,964.80 美元。出售完成后，首席执行官持有该公司 597,405 股股票，价值约为 12,641,089.80 美元。这笔交易代表其持股减少了 3.13%。该出售在与 SEC 的法律文件中披露，您可以通过此超链接访问。在过去的九十天里，内部人士出售了 29,636 股公司股票，价值 625,949 美元。当前 4.40% 的股票由公司内部人士持有。</p>
<h2>CareDx 的机构交易</h2>
<p>一些对冲基金和其他机构投资者最近对该股票的持仓进行了调整。维吉尼亚退休系统等在第二季度购买了 CareDx 的新头寸，价值 352,000 美元。Hood River Capital Management LLC 在第二季度将其在 CareDx 的股份增加了 11.5%。Hood River Capital Management LLC 现在拥有 1,765,981 股该公司的股票，价值 34,507,000 美元，在此期间又购买了 182,025 股。Envestnet Asset Management Inc.在第二季度将其在 CareDx 的持仓增加了 17.7%。Envestnet Asset Management Inc.现在拥有 22,489 股该公司的股票，价值 439,000 美元，在此期间又购买了 3,389 股。Geode Capital Management LLC 在第二季度将其在 CareDx 的持仓增加了 3.4%。Geode Capital Management LLC 现在拥有 1,323,497 股该公司的股票，价值 25,864,000 美元，在上个季度又购买了 43,074 股。最后，Zweig DiMenna Associates LLC 在第二季度购买了 CareDx 的新股份，价值约 4,428,000 美元。</p>
<h2>关于 CareDx</h2>
<p>（获取免费报告）</p>
<p>CareDx, Inc. 纳斯达克：CDNA 是一家专注于移植患者护理的精准诊断公司。该公司开发和商业化非侵入性测试，旨在检测器官移植排斥和感染风险，帮助医生在移植后的管理过程中做出明智的决策。</p>
<p>该公司的核心产品组合包括 AlloMap®，一种用于心脏移植受者的基因表达分析测试，以及 AlloSure®，一种主要用于肾脏移植监测的供体衍生无细胞 DNA 检测。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们更看好的股票比 CareDx 更好</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>黄金市场崩溃的那一天</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>你的银行账户不再安全</li>
<li>他刚刚准确预测了另一个黄金走势……</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0ROQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0ROQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 CareDx 吗？</h2>
<p>在考虑 CareDx 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 CareDx 并不在名单上。</p>
<p>虽然 CareDx 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>华尔街禅将 CareDx (NASDAQ:CDNA) 的评级从 “买入” 下调至 “持有”。其他分析师的看法不一，BTIG Research 将目标价上调至 25 美元，并维持 “买入” 评级，而 Weiss Ratings 和 Craig Hallum 则给予 “持有” 评级。CareDx 报告的季度每股收益为 0.28 美元，超出预期，营收同比增长 20.7%。该股开盘价为 19.47 美元，市值为 10 亿美元。内部交易活动包括首席执行官出售股份，机构投资者已调整其在该股中的持仓</p>

<p>CareDx (NASDAQ:CDNA - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report issued on Saturday.</p>
<div class="lb-trans"><p>CareDx（纳斯达克：CDNA - 获取免费报告）在周六发布的研究报告中被华尔街 Zen 的投资分析师从 “买入” 评级下调至 “持有” 评级。</p>
</div><p>A number of other equities research analysts also recently weighed in on CDNA. BTIG Research lifted their price target on shares of CareDx from $22.00 to $25.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, November 6th. Weiss Ratings reissued a &#34;hold (c-)&#34; rating on shares of CareDx in a research note on Monday, December 29th. Craig Hallum cut CareDx from a &#34;buy&#34; rating to a &#34;hold&#34; rating and set a $26.00 price target for the company. in a research note on Tuesday, January 6th. Zacks Research raised shares of CareDx from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, November 18th. Finally, Wells Fargo &amp; Company increased their target price on shares of CareDx from $14.00 to $18.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Monday, December 15th. Three investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of &#34;Hold&#34; and an average price target of $26.67.</p>
<div class="lb-trans"><p>其他一些股票研究分析师最近也对 CDNA 发表了看法。BTIG Research 在 11 月 6 日的研究报告中将 CareDx 的目标价格从 22.00 美元上调至 25.00 美元，并给予该公司 “买入” 评级。Weiss Ratings 在 12 月 29 日的研究报告中重新发布了对 CareDx 的 “持有（c-）” 评级。Craig Hallum 在 1 月 6 日的研究报告中将 CareDx 的评级从 “买入” 下调至 “持有”，并设定了 26.00 美元的目标价格。Zacks Research 在 11 月 18 日的研究报告中将 CareDx 的评级从 “强烈卖出” 上调至 “持有”。最后，富国银行在 12 月 15 日的研究报告中将 CareDx 的目标价格从 14.00 美元上调至 18.00 美元，并给予该股票 “等权重” 评级。三位投资分析师对该股票给予了 “买入” 评级，六位分析师对该公司给予了 “持有” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “持有”，平均目标价格为 26.67 美元。</p>
</div><p><strong>View Our Latest Analysis on CDNA</strong></p>
<div class="lb-trans"><p><strong>查看我们对 CDNA 的最新分析</strong></p>
</div><h2>CareDx Stock Up 6.1%</h2>
<div class="lb-trans"><h2>CareDx 股票上涨 6.1%</h2>
</div><p>NASDAQ:CDNA opened at $19.47 on Friday. The firm has a market capitalization of $1.00 billion, a P/E ratio of 16.36 and a beta of 2.51. CareDx has a 12-month low of $10.96 and a 12-month high of $25.55. The stock's fifty day simple moving average is $19.56 and its 200-day simple moving average is $16.11.</p>
<div class="lb-trans"><p>纳斯达克：CDNA 周五开盘价为 19.47 美元。该公司的市值为 10 亿美元，市盈率为 16.36，贝塔值为 2.51。CareDx 的 12 个月低点为 10.96 美元，12 个月高点为 25.55 美元。该股票的 50 日简单移动平均线为 19.56 美元，200 日简单移动平均线为 16.11 美元。</p>
</div><p>CareDx (NASDAQ:CDNA - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.28 earnings per share for the quarter, beating analysts' consensus estimates of $0.13 by $0.15. CareDx had a net margin of 19.65% and a return on equity of 20.15%. The business had revenue of $100.06 million for the quarter, compared to the consensus estimate of $95.25 million. During the same period last year, the company posted ($0.14) EPS. CareDx's revenue for the quarter was up 20.7% on a year-over-year basis. As a group, equities research analysts expect that CareDx will post -0.9 earnings per share for the current year.</p>
<div class="lb-trans"><p>CareDx（纳斯达克：CDNA - 获取免费报告）最后一次公布季度财报是在 11 月 4 日。该公司报告每股收益为 0.28 美元，超出分析师的共识预期 0.13 美元，超出幅度为 0.15 美元。CareDx 的净利润率为 19.65%，股本回报率为 20.15%。该季度的营业收入为 1 亿 006 万美元，而共识预期为 9,525 万美元。去年同期，该公司每股收益为（0.14）美元。CareDx 本季度的收入同比增长 20.7%。整体来看，股票研究分析师预计 CareDx 在本年度的每股收益为-0.9 美元。</p>
</div><h2>Insider Buying and Selling at CareDx</h2>
<div class="lb-trans"><h2>CareDx 的内部买卖</h2>
</div><p>In related news, CEO John Walter Hanna, Jr. sold 19,280 shares of CareDx stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $21.16, for a total value of $407,964.80. Following the completion of the sale, the chief executive officer owned 597,405 shares of the company's stock, valued at approximately $12,641,089.80. This trade represents a 3.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders sold 29,636 shares of company stock worth $625,949. 4.40% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，首席执行官 John Walter Hanna, Jr.于 1 月 22 日星期四出售了 19,280 股 CareDx 股票。该股票以平均价格 21.16 美元出售，总价值为 407,964.80 美元。出售完成后，首席执行官持有该公司 597,405 股股票，价值约为 12,641,089.80 美元。这笔交易代表其持股减少了 3.13%。该出售在与 SEC 的法律文件中披露，您可以通过此超链接访问。在过去的九十天里，内部人士出售了 29,636 股公司股票，价值 625,949 美元。当前 4.40% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Trading of CareDx</h2>
<div class="lb-trans"><h2>CareDx 的机构交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of CareDx in the second quarter worth $352,000. Hood River Capital Management LLC increased its stake in CareDx by 11.5% in the 2nd quarter. Hood River Capital Management LLC now owns 1,765,981 shares of the company's stock worth $34,507,000 after purchasing an additional 182,025 shares during the period. Envestnet Asset Management Inc. increased its position in shares of CareDx by 17.7% in the second quarter. Envestnet Asset Management Inc. now owns 22,489 shares of the company's stock valued at $439,000 after acquiring an additional 3,389 shares during the period. Geode Capital Management LLC grew its position in shares of CareDx by 3.4% in the 2nd quarter. Geode Capital Management LLC now owns 1,323,497 shares of the company's stock worth $25,864,000 after buying an additional 43,074 shares during the last quarter. Finally, Zweig DiMenna Associates LLC purchased a new stake in shares of CareDx in the 2nd quarter worth about $4,428,000.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近对该股票的持仓进行了调整。维吉尼亚退休系统等在第二季度购买了 CareDx 的新头寸，价值 352,000 美元。Hood River Capital Management LLC 在第二季度将其在 CareDx 的股份增加了 11.5%。Hood River Capital Management LLC 现在拥有 1,765,981 股该公司的股票，价值 34,507,000 美元，在此期间又购买了 182,025 股。Envestnet Asset Management Inc.在第二季度将其在 CareDx 的持仓增加了 17.7%。Envestnet Asset Management Inc.现在拥有 22,489 股该公司的股票，价值 439,000 美元，在此期间又购买了 3,389 股。Geode Capital Management LLC 在第二季度将其在 CareDx 的持仓增加了 3.4%。Geode Capital Management LLC 现在拥有 1,323,497 股该公司的股票，价值 25,864,000 美元，在上个季度又购买了 43,074 股。最后，Zweig DiMenna Associates LLC 在第二季度购买了 CareDx 的新股份，价值约 4,428,000 美元。</p>
</div><h2>About CareDx</h2>
<div class="lb-trans"><h2>关于 CareDx</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>CareDx, Inc NASDAQ: CDNA is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.</p>
<div class="lb-trans"><p>CareDx, Inc. 纳斯达克：CDNA 是一家专注于移植患者护理的精准诊断公司。该公司开发和商业化非侵入性测试，旨在检测器官移植排斥和感染风险，帮助医生在移植后的管理过程中做出明智的决策。</p>
</div><p>The company's core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.</p>
<div class="lb-trans"><p>该公司的核心产品组合包括 AlloMap®，一种用于心脏移植受者的基因表达分析测试，以及 AlloSure®，一种主要用于肾脏移植监测的供体衍生无细胞 DNA 检测。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than CareDx</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>The day the gold market broke</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>He just nailed another gold prediction …</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 CareDx 更好</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>黄金市场崩溃的那一天</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>你的银行账户不再安全</li>
<li>他刚刚准确预测了另一个黄金走势……</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0ROQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CDNA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CareDx Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 CareDx 吗？</h2>
</div><p>Before you consider CareDx, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 CareDx 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareDx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 CareDx 并不在名单上。</p>
</div><p>While CareDx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 CareDx 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

CareDx（NASDAQ:CDNA）在 Wall Street Zen 被下调至 “持有” 评级